Abstract:Background: Neuronal abnormalities are closely associated with major depressive disorder (MDD). Available evidence suggests a role for microRNAs (miRNAs) in regulating the expression of genes involved in MDD. Hence, miRNAs that can be potential therapeutic targets need to be identified. Methods: A mouse model of chronic unpredictable stress (CUS) was used to evaluate the function of miRNAs in MDD. miR-144-5p was screened from the hippocampi of CUS mice based on sequencing results. Adenovirus-associated vectors were used to overexpress or knockdown miR-144-5p in mice. BpV(pic) and LY294002 were used to determine the relationship between miR-144-5p target genes PTEN and TLR4 in neuronal impairment caused by miR-144-5p deficiency. Western blotting, immunofluorescence, ELISA immunosorbent assay, and Golgi staining were used to detect neuronal abnormalities. Serum samples from healthy individuals and patients with MDD were used to detect miR-144-5p levels in the serum and serum exosomes using qRT-PCR. Results: miR-144-5p expression was significantly decreased within the hippocampal dentate gyrus (DG) of CUS mice. Upregulation of miR-144-5p in the DG ameliorated depression-like behavior in CUS mice and attenuated neuronal abnormalities by directly targeting PTEN and TLR4 expression. Furthermore, miR-144-5p knockdown in normal mice led to depression-like behavior via inducing neuronal abnormalities, including abnormal neurogenesis, neuronal apoptosis, altered synaptic plasticity, and neuroinflammation. miR-144-5p deficiency-mediated neuronal impairment was mediated by PI3K/Akt/FoxO1 signaling. Furthermore, miR-144-5p levels were downregulated in the sera of patients with MDD and associated with depressive symptoms. Consistently, serum exosome-derived miR-144-5p levels were decreased in patients with MDD. Conclusion: miR-144-5p plays a vital role in regulating neuronal abnormalities in depression. Our findings provide translational evidence that miR-144-5p is a new potential therapeutic target for MDD.

Evidence for the Contribution of the miR-206/BDNF Pathway in the Pathophysiology of Depression

Blood Mir-144-3p: a Novel Diagnostic and Therapeutic Tool for Depression

Prospective Role of MicroRNAs in Depression

Hippocampal miR-206-3p participates in the pathogenesis of depression via regulating the expression of BDNF

MiRNA-206 and BDNF Genes Interacted in Bipolar I Disorder.

The Link Between Long Noncoding RNAs and Depression.

Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression

lncRNA MIR155HG Alleviates Depression-Like Behaviors in Mice by Regulating the miR-155/BDNF Axis

Exploring the Association between BDNF related Signaling Pathways and Depression: A Literature Review

The role of microRNAs in depression

MicroRNA-451a is a candidate biomarker and therapeutic target for major depressive disorder

Hippocampal miR-211-5p regulates neurogenesis and depression-like behaviors in the rat

Deciphering the role of miRNA-134 in the pathophysiology of depression: A comprehensive review

Clinical and preclinical evaluation of miR-144-5p as a key target for major depressive disorder

BDNF gene hydroxymethylation in hippocampus related to neuroinflammation-induced depression-like behaviors in mice

A review of DNA methylation in depression

Upregulation of miR-195a inhibits brain-derived neurotrophic factor in mouse hippocampus and may contribute to depression-like behaviors induced by chronic social stress

The Associations Between DNA Methylation and Depression: A Systematic Review and Meta-Analysis

MicroRNA132 associated multimodal neuroimaging patterns in unmedicated major depressive disorder.

MiR-184-3p in the paraventricular nucleus participates in the neurobiology of depression via regulation of the hypothalamus-pituitary-adrenal axis

The involvement of ADAR1 in antidepressant action by regulating BDNF via miR-432